What is the recommended acute management for an intracerebral hemorrhagic stroke?

Acute Management of Intracerebral Hemorrhagic Stroke

For acute intracerebral hemorrhage (ICH), immediately obtain non-contrast CT imaging, admit to a stroke unit or neurocritical care unit, reverse any coagulopathy, lower blood pressure carefully to 130-140 mmHg systolic (avoiding drops ≥60 mmHg within 1 hour), obtain serial CT imaging within 24 hours to monitor for hematoma expansion, and consider neurosurgical consultation for appropriate candidates. 1, 2

Immediate Diagnostic Evaluation

Neuroimaging

• Obtain rapid non-contrast CT or MRI immediately to confirm ICH diagnosis and distinguish from ischemic stroke 1
• Calculate hematoma volume using the ABC/2 formula for prognostication 1
• Perform CT angiography (CTA) within the first few hours to identify the "spot sign" which predicts hematoma expansion risk, though its sensitivity is time-dependent and highest within 0-2 hours of symptom onset 1
• Obtain serial head CT at approximately 6 and 24 hours after onset to detect hematoma expansion, which occurs in 26% of patients within 1 hour and an additional 12% by 20 hours 1, 2

Critical Laboratory Assessment

• Check INR, platelet count, and coagulation studies immediately 1
• Measure troponin (elevated levels associated with increased in-hospital mortality) 1
• Assess renal function and glucose (both hyperglycemia and renal failure predict poor outcomes) 1
• Evaluate for anemia and thrombocytopenia (both associated with hemorrhagic expansion and worse outcomes) 1

Acute Medical Management

Blood Pressure Control

Target systolic blood pressure of 120-140 mmHg, but avoid reductions ≥60 mmHg within 1 hour 3, 2

• Careful, targeted, and sustained BP lowering during the first 24 hours may reduce hematoma growth and improve functional outcomes 3
• Minimize blood pressure variability for optimal outcomes 3

Coagulopathy Reversal

Reverse anticoagulation immediately as anticoagulant-related hemorrhages are associated with increased hematoma volume, expansion, morbidity, and mortality 1, 3

• For warfarin: Administer prothrombin complex concentrate (PCC) 3, 2
• For dabigatran: Give idarucizumab 3
• For anti-Xa agents (rivaroxaban, apixaban): Use PCC or andexanet alfa where available 3
• Avoid platelet transfusions for antiplatelet-associated ICH (weak evidence against routine use) 2

Intracranial Pressure Management

• Obtain repeat CT imaging beyond 24 hours if neurological deterioration occurs or in patients with low Glasgow Coma Scale scores to evaluate for hydrocephalus, brain swelling, or herniation 1
• Consider external ventricular drainage with intraventricular thrombolysis for intraventricular extension 2

Admission and Monitoring

Unit Selection

Admit all ICH patients to an organized stroke unit or neurocritical care unit - this is strongly recommended and improves outcomes 3, 2

• Expert supportive care on specialized units reduces mortality and improves functional outcomes 3

Avoid Early Prognostication Pitfalls

Do not issue early do-not-resuscitate orders or withdraw active care within the first 24-48 hours - early prognostication is difficult and should be used judiciously 3

Neurosurgical Considerations

Indications for Surgical Consultation

• Cerebellar ICH >15 mL (weak evidence for evacuation) 2
• Supratentorial ICH with neurological deterioration - consider minimally invasive surgery or open craniotomy (weak evidence, but meta-analyses suggest increased likelihood of good functional outcome with surgery) 3, 2
• Hydrocephalus requiring external ventricular drainage 1, 2

Note: No large phase III trial has shown overall benefit for surgery, but 35% of ICU patients required emergency neurosurgical interventions after admission 1

Supportive Care Measures

Venous Thromboembolism Prevention

Use intermittent pneumatic compression to prevent proximal deep vein thrombosis 2

Avoid Routine Interventions Without Evidence

• Do not routinely use recombinant factor VIIa (weak evidence against) 2
• Do not use prophylactic anti-seizure medications routinely 2
• Do not use anti-inflammatory drugs outside clinical trials (strong evidence against) 2
• Do not routinely use prophylactic antibiotics or prokinetic anti-emetics 2

Care Bundle Approach

Implement a standardized ICH care bundle with regular monitoring and process improvement to ensure consistent optimal care for all patients 3, 4